カテゴリー： Market Monitor Global, 世界, 医療/バイオ

筋強直性ジストロフィー治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Myotonic Dystrophy Treatment Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5790）◆商品コード：MMG23JU5790
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月
◆ページ数：69
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Myotonic Dystrophy Treatment Market 調査レポートは次の情報を含め、グローバルにおけるの筋強直性ジストロフィー治療薬市場規模と予測を収録しています。・世界の筋強直性ジストロフィー治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の筋強直性ジストロフィー治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の筋強直性ジストロフィー治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ナトリウムチャネル遮断薬」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

筋強直性ジストロフィー治療薬のグローバル主要企業は、Lupin、 Teva、 ANI Pharmaceuticals、 Mylan、 Novartis、 Sun Pharma、 Mallinckrodtなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、筋強直性ジストロフィー治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の筋強直性ジストロフィー治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の筋強直性ジストロフィー治療薬市場：タイプ別市場シェア、2022年
・ナトリウムチャネル遮断薬、三環系抗うつ薬、その他

世界の筋強直性ジストロフィー治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の筋強直性ジストロフィー治療薬市場：用途別市場シェア、2022年
・病院薬局、小売薬局、その他

世界の筋強直性ジストロフィー治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の筋強直性ジストロフィー治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における筋強直性ジストロフィー治療薬のグローバル売上、2018年-2023年
・主要企業における筋強直性ジストロフィー治療薬のグローバル売上シェア、2022年
・主要企業における筋強直性ジストロフィー治療薬のグローバル販売量、2018年-2023年
・主要企業における筋強直性ジストロフィー治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Lupin、 Teva、 ANI Pharmaceuticals、 Mylan、 Novartis、 Sun Pharma、 Mallinckrodt

*************************************************************

・調査・分析レポートの概要
筋強直性ジストロフィー治療薬市場の定義
市場セグメント
世界の筋強直性ジストロフィー治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の筋強直性ジストロフィー治療薬市場規模
世界の筋強直性ジストロフィー治療薬市場規模：2022年 VS 2029年
世界の筋強直性ジストロフィー治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの筋強直性ジストロフィー治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の筋強直性ジストロフィー治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：ナトリウムチャネル遮断薬、三環系抗うつ薬、その他
筋強直性ジストロフィー治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院薬局、小売薬局、その他
筋強直性ジストロフィー治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別筋強直性ジストロフィー治療薬市場規模 2022年と2029年
地域別筋強直性ジストロフィー治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Lupin、 Teva、 ANI Pharmaceuticals、 Mylan、 Novartis、 Sun Pharma、 Mallinckrodt
...

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.
This report aims to provide a comprehensive presentation of the global market for Myotonic Dystrophy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myotonic Dystrophy Treatment. This report contains market size and forecasts of Myotonic Dystrophy Treatment in global, including the following market information:
Global Myotonic Dystrophy Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Myotonic Dystrophy Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Sodium Channel Blocker Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Myotonic Dystrophy Treatment include Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, Sun Pharma and Mallinckrodt, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Myotonic Dystrophy Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Myotonic Dystrophy Treatment Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Myotonic Dystrophy Treatment Market Segment Percentages, by Type, 2022 (%)
Sodium Channel Blocker
Tricyclic Antidepressant
Others
Global Myotonic Dystrophy Treatment Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Myotonic Dystrophy Treatment Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacy
Retail Pharmacy
Others
Global Myotonic Dystrophy Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Myotonic Dystrophy Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Myotonic Dystrophy Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Myotonic Dystrophy Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Lupin
Teva
ANI Pharmaceuticals
Mylan
Novartis
Sun Pharma
Mallinckrodt
Outline of Major Chapters:
Chapter 1: Introduces the definition of Myotonic Dystrophy Treatment, market overview.
Chapter 2: Global Myotonic Dystrophy Treatment market size in revenue.
Chapter 3: Detailed analysis of Myotonic Dystrophy Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Myotonic Dystrophy Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Myotonic Dystrophy Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Myotonic Dystrophy Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Myotonic Dystrophy Treatment Overall Market Size
2.1 Global Myotonic Dystrophy Treatment Market Size: 2022 VS 2029
2.2 Global Myotonic Dystrophy Treatment Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Myotonic Dystrophy Treatment Players in Global Market
3.2 Top Global Myotonic Dystrophy Treatment Companies Ranked by Revenue
3.3 Global Myotonic Dystrophy Treatment Revenue by Companies
3.4 Top 3 and Top 5 Myotonic Dystrophy Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Myotonic Dystrophy Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Myotonic Dystrophy Treatment Players in Global Market
3.6.1 List of Global Tier 1 Myotonic Dystrophy Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Myotonic Dystrophy Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Myotonic Dystrophy Treatment Market Size Markets, 2022 & 2029
4.1.2 Sodium Channel Blocker
4.1.3 Tricyclic Antidepressant
4.1.4 Others
4.2 By Type – Global Myotonic Dystrophy Treatment Revenue & Forecasts
4.2.1 By Type – Global Myotonic Dystrophy Treatment Revenue, 2018-2023
4.2.2 By Type – Global Myotonic Dystrophy Treatment Revenue, 2024-2029
4.2.3 By Type – Global Myotonic Dystrophy Treatment Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Myotonic Dystrophy Treatment Market Size, 2022 & 2029
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.1.4 Others
5.2 By Application – Global Myotonic Dystrophy Treatment Revenue & Forecasts
5.2.1 By Application – Global Myotonic Dystrophy Treatment Revenue, 2018-2023
5.2.2 By Application – Global Myotonic Dystrophy Treatment Revenue, 2024-2029
5.2.3 By Application – Global Myotonic Dystrophy Treatment Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Myotonic Dystrophy Treatment Market Size, 2022 & 2029
6.2 By Region – Global Myotonic Dystrophy Treatment Revenue & Forecasts
6.2.1 By Region – Global Myotonic Dystrophy Treatment Revenue, 2018-2023
6.2.2 By Region – Global Myotonic Dystrophy Treatment Revenue, 2024-2029
6.2.3 By Region – Global Myotonic Dystrophy Treatment Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Myotonic Dystrophy Treatment Revenue, 2018-2029
6.3.2 US Myotonic Dystrophy Treatment Market Size, 2018-2029
6.3.3 Canada Myotonic Dystrophy Treatment Market Size, 2018-2029
6.3.4 Mexico Myotonic Dystrophy Treatment Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Myotonic Dystrophy Treatment Revenue, 2018-2029
6.4.2 Germany Myotonic Dystrophy Treatment Market Size, 2018-2029
6.4.3 France Myotonic Dystrophy Treatment Market Size, 2018-2029
6.4.4 U.K. Myotonic Dystrophy Treatment Market Size, 2018-2029
6.4.5 Italy Myotonic Dystrophy Treatment Market Size, 2018-2029
6.4.6 Russia Myotonic Dystrophy Treatment Market Size, 2018-2029
6.4.7 Nordic Countries Myotonic Dystrophy Treatment Market Size, 2018-2029
6.4.8 Benelux Myotonic Dystrophy Treatment Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Myotonic Dystrophy Treatment Revenue, 2018-2029
6.5.2 China Myotonic Dystrophy Treatment Market Size, 2018-2029
6.5.3 Japan Myotonic Dystrophy Treatment Market Size, 2018-2029
6.5.4 South Korea Myotonic Dystrophy Treatment Market Size, 2018-2029
6.5.5 Southeast Asia Myotonic Dystrophy Treatment Market Size, 2018-2029
6.5.6 India Myotonic Dystrophy Treatment Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Myotonic Dystrophy Treatment Revenue, 2018-2029
6.6.2 Brazil Myotonic Dystrophy Treatment Market Size, 2018-2029
6.6.3 Argentina Myotonic Dystrophy Treatment Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Myotonic Dystrophy Treatment Revenue, 2018-2029
6.7.2 Turkey Myotonic Dystrophy Treatment Market Size, 2018-2029
6.7.3 Israel Myotonic Dystrophy Treatment Market Size, 2018-2029
6.7.4 Saudi Arabia Myotonic Dystrophy Treatment Market Size, 2018-2029
6.7.5 UAE Myotonic Dystrophy Treatment Market Size, 2018-2029
7 Myotonic Dystrophy Treatment Companies Profiles
7.1 Lupin
7.1.1 Lupin Company Summary
7.1.2 Lupin Business Overview
7.1.3 Lupin Myotonic Dystrophy Treatment Major Product Offerings
7.1.4 Lupin Myotonic Dystrophy Treatment Revenue in Global Market (2018-2023)
7.1.5 Lupin Key News & Latest Developments
7.2 Teva
7.2.1 Teva Company Summary
7.2.2 Teva Business Overview
7.2.3 Teva Myotonic Dystrophy Treatment Major Product Offerings
7.2.4 Teva Myotonic Dystrophy Treatment Revenue in Global Market (2018-2023)
7.2.5 Teva Key News & Latest Developments
7.3 ANI Pharmaceuticals
7.3.1 ANI Pharmaceuticals Company Summary
7.3.2 ANI Pharmaceuticals Business Overview
7.3.3 ANI Pharmaceuticals Myotonic Dystrophy Treatment Major Product Offerings
7.3.4 ANI Pharmaceuticals Myotonic Dystrophy Treatment Revenue in Global Market (2018-2023)
7.3.5 ANI Pharmaceuticals Key News & Latest Developments
7.4 Mylan
7.4.1 Mylan Company Summary
7.4.2 Mylan Business Overview
7.4.3 Mylan Myotonic Dystrophy Treatment Major Product Offerings
7.4.4 Mylan Myotonic Dystrophy Treatment Revenue in Global Market (2018-2023)
7.4.5 Mylan Key News & Latest Developments
7.5 Novartis
7.5.1 Novartis Company Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Myotonic Dystrophy Treatment Major Product Offerings
7.5.4 Novartis Myotonic Dystrophy Treatment Revenue in Global Market (2018-2023)
7.5.5 Novartis Key News & Latest Developments
7.6 Sun Pharma
7.6.1 Sun Pharma Company Summary
7.6.2 Sun Pharma Business Overview
7.6.3 Sun Pharma Myotonic Dystrophy Treatment Major Product Offerings
7.6.4 Sun Pharma Myotonic Dystrophy Treatment Revenue in Global Market (2018-2023)
7.6.5 Sun Pharma Key News & Latest Developments
7.7 Mallinckrodt
7.7.1 Mallinckrodt Company Summary
7.7.2 Mallinckrodt Business Overview
7.7.3 Mallinckrodt Myotonic Dystrophy Treatment Major Product Offerings
7.7.4 Mallinckrodt Myotonic Dystrophy Treatment Revenue in Global Market (2018-2023)
7.7.5 Mallinckrodt Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Myotonic Dystrophy Treatment Market Opportunities & Trends in Global Market
Table 2. Myotonic Dystrophy Treatment Market Drivers in Global Market
Table 3. Myotonic Dystrophy Treatment Market Restraints in Global Market
Table 4. Key Players of Myotonic Dystrophy Treatment in Global Market
Table 5. Top Myotonic Dystrophy Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Myotonic Dystrophy Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Myotonic Dystrophy Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Myotonic Dystrophy Treatment Product Type
Table 9. List of Global Tier 1 Myotonic Dystrophy Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Myotonic Dystrophy Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Myotonic Dystrophy Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Myotonic Dystrophy Treatment Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Myotonic Dystrophy Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Myotonic Dystrophy Treatment Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Myotonic Dystrophy Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Myotonic Dystrophy Treatment Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2024-2029
Table 30. Lupin Company Summary
Table 31. Lupin Myotonic Dystrophy Treatment Product Offerings
Table 32. Lupin Myotonic Dystrophy Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. Lupin Key News & Latest Developments
Table 34. Teva Company Summary
Table 35. Teva Myotonic Dystrophy Treatment Product Offerings
Table 36. Teva Myotonic Dystrophy Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. Teva Key News & Latest Developments
Table 38. ANI Pharmaceuticals Company Summary
Table 39. ANI Pharmaceuticals Myotonic Dystrophy Treatment Product Offerings
Table 40. ANI Pharmaceuticals Myotonic Dystrophy Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. ANI Pharmaceuticals Key News & Latest Developments
Table 42. Mylan Company Summary
Table 43. Mylan Myotonic Dystrophy Treatment Product Offerings
Table 44. Mylan Myotonic Dystrophy Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. Mylan Key News & Latest Developments
Table 46. Novartis Company Summary
Table 47. Novartis Myotonic Dystrophy Treatment Product Offerings
Table 48. Novartis Myotonic Dystrophy Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. Novartis Key News & Latest Developments
Table 50. Sun Pharma Company Summary
Table 51. Sun Pharma Myotonic Dystrophy Treatment Product Offerings
Table 52. Sun Pharma Myotonic Dystrophy Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. Sun Pharma Key News & Latest Developments
Table 54. Mallinckrodt Company Summary
Table 55. Mallinckrodt Myotonic Dystrophy Treatment Product Offerings
Table 56. Mallinckrodt Myotonic Dystrophy Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. Mallinckrodt Key News & Latest Developments
List of Figures
Figure 1. Myotonic Dystrophy Treatment Segment by Type in 2022
Figure 2. Myotonic Dystrophy Treatment Segment by Application in 2022
Figure 3. Global Myotonic Dystrophy Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Myotonic Dystrophy Treatment Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Myotonic Dystrophy Treatment Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Myotonic Dystrophy Treatment Revenue in 2022
Figure 8. By Type - Global Myotonic Dystrophy Treatment Revenue Market Share, 2018-2029
Figure 9. By Application - Global Myotonic Dystrophy Treatment Revenue Market Share, 2018-2029
Figure 10. By Type - Global Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Myotonic Dystrophy Treatment Revenue Market Share, 2018-2029
Figure 12. By Application - Global Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Myotonic Dystrophy Treatment Revenue Market Share, 2018-2029
Figure 14. By Region - Global Myotonic Dystrophy Treatment Revenue Market Share, 2018-2029
Figure 15. By Country - North America Myotonic Dystrophy Treatment Revenue Market Share, 2018-2029
Figure 16. US Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Myotonic Dystrophy Treatment Revenue Market Share, 2018-2029
Figure 20. Germany Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 21. France Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Myotonic Dystrophy Treatment Revenue Market Share, 2018-2029
Figure 28. China Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 32. India Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Myotonic Dystrophy Treatment Revenue Market Share, 2018-2029
Figure 34. Brazil Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Myotonic Dystrophy Treatment Revenue Market Share, 2018-2029
Figure 37. Turkey Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Myotonic Dystrophy Treatment Revenue, (US$, Mn), 2018-2029
Figure 41. Lupin Myotonic Dystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Teva Myotonic Dystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. ANI Pharmaceuticals Myotonic Dystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Mylan Myotonic Dystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Novartis Myotonic Dystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Sun Pharma Myotonic Dystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Mallinckrodt Myotonic Dystrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 筋強直性ジストロフィー治療薬の世界市場見通し2023年-2029年(Myotonic Dystrophy Treatment Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 筋強直性ジストロフィー1型（DM1）の世界市場見通し2023年-2029年
  • 眼咽頭型筋ジストロフィー（OPMD）の世界市場見通し2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆